Bindarit

Research use only, not for human use.

Bindarit exhibits selective inhibition against monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8.

Bindarit exhibits selective inhibition against monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8.(In Vitro):Bindarit (10-300 μM; 48 hours) at 100 μM and 300 μM significantly inhibits platelet derived growth factor-BB (PDGF-BB)-induced rat VSMCs proliferation by 27% and 42%, respectively.(In Vivo):Bindarit (50 mg/kg; oral administration; every day; for 4 months, 6 months, 8 months; NZB/W F1 female mice) delays the onset of proteinuria and significantly protects from renal function impairment. Bindarit completely prevents monocyte chemoattractant protein (MCP-1) up-regulation.

Cell Viability AssayCell Line:VSMC cells Concentration:10 μM, 30 μM, 100 μM, 300 μM Incubation Time:48 hours Result:Inhibited PDGF-BB-induced rat VSMCs proliferation.

Animal Model:NZB/W F1 female mice ( two months of age)Dosage:50 mg/kg Administration:Oral administration; every day; for 4 months, 6 months, 8 months Result:Delayed the onset of proteinuria and significantly protected from renal function impairment.

AF 2838

Autophagy

CCR

MCP-1/CCL2| MCP-2/CCL8| MCP-3/CCL7

Inflammation/Immunology

——

130641-38-2

324.37

C19H20N2O3

>98% (HPLC)

DMSO:65 mg/mL (200.38 mM); Ethanol:65 mg/mL (200.38 mM); Water:<1 mg/mL (<1 mM)

CC(C)(OCC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3)C(O)=O

2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid

(-20℃)

With Ice Pack

≥ 2 years